trending Market Intelligence /marketintelligence/en/news-insights/trending/CYM8mNdCaURNGPQR3XrgDA2 content esgSubNav
In This List

Albireo Pharma seeks approval for chronic constipation drug in Japan

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Albireo Pharma seeks approval for chronic constipation drug in Japan

Albireo Pharma Inc. said EA Pharma Co. Ltd. filed a new drug application to the Japanese Pharmaceuticals and Medical Devices Agency for elobixibat, a chronic constipation drug.

EA Pharma holds the exclusive license for elobixibat as gastrointestinal disorder treatment in Japan and other select countries in Asia.

If approved, EA Pharma will co-market the drug in Japan with Mochida Pharmaceutical Co. Ltd.

Elobixibat is an orally available ileal bile acid transporter inhibitor that helps improve secretion and motility in the large bowel. In a phase 3 clinical trial, the drug met the primary endpoint, change in the number of weekly spontaneous bowel movements from baseline to the first treatment week compared with placebo, with high statistical significance.